15/4/2019 – an update of this document has been published below, the main amendment is a strengthening of the advice on prescribing by brand name.
Transdermal buprenorphine patches are widely prescribed and available from a variety of manufacturers. A number of patient safety incidents have occurred in the use of transdermal opiate patches and concerns have been raised nationally about errors seen with these products.
There are two groups of buprenorphine patches, lower strength and higher strength and there are at least 8 different brands and 21 individual preparations in each of the low and high strength categories. This Q&A aims to cover a number of topics in order to improve the safety of buprenorphine patch prescribing and administration, as well as highlighting some of the concerns. This Q&A does not compare the costs of the various transdermal buprenorphine products.